B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Early SARS-CoV-2 Infection Events

REACTOME PATHWAY
Reactome: R-HSA-97725725 genes13 compounds

The Early SARS-CoV-2 Infection Events pathway (Reactome ID: R-HSA-9772572) involves 5 genes and is affected by 13 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.

Genes in this Pathway

CTSLFURINMAP1LC3BPIK3C3VCP

Compounds Affecting Early SARS-CoV-2 Infection Events

#CompoundTargets HitStudies
1Hexachlorophene300
2Oxytetracycline300
3egcg300
4Clotrimazole296
5Demeclocycline5
6Edaravone298
7torin 110
8pictilisib25
9Wortmannin300
10Diminazene300
11silver sulfadiazine299
12Novobiocin300
13Triamcinolone300

About the Early SARS-CoV-2 Infection Events Pathway

The Early SARS-CoV-2 Infection Events pathway is catalogued in Reactome (ID: R-HSA-9772572) and involves 5 genes. In the BiohacksAI corpus, 13 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include CTSL, FURIN, MAP1LC3B, PIK3C3, VCP.